HK Stock Market Move | ZAI LAB(09688) rose more than 7% against the market recently. Zoci was recently granted orphan drug designation by the European Medicines Agency.

ZAI LAB (09688) rose more than 7% against the market, as of the time of publication, up 6.27% to HKD 14.4, with a turnover of HKD 72.54 million. On the news front, according to ZAI LAB's official WeChat account, the European Medicines Agency has granted orphan drug status to zocilurtatug pelitecan (zoci, formerly known as ZL-1310), an antibody-drug conjugate targeting Delta-like ligand 3 (DLL3) with groundbreaking potential, for the treatment of neuroendocrine cancer originating from the lungs. Previously, the FDA had granted zoci fast track designation (FTD) and orphan drug status for the treatment of small cell lung cancer. The FDA has also recently granted FTD for the treatment of neuroendocrine cancer outside the lungs with zoci. Zoci is a new ADC targeting DLL3. DLL3 is a validated therapeutic target that is overexpressed in various neuroendocrine tumors, including small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinomas (epNECs), and is often associated with poor clinical prognosis. Zoci is expected to be ZAI LAB's first globally marketed anti-cancer product, with plans to conduct three registration studies by the end of 2026, involving second-line and above SCLC, first-line SCLC, and extrapulmonary neuroendocrine cancer.